Evidence map›Paper›PMID 25394492›Full record

ArticleDiagnostic pathology2014

MicroRNA-7 directly targets insulin-like growth factor 1 receptor to inhibit cellular growth and glucose metabolism in gliomas.

Bo Wang, Fei Sun, Nan Dong, Zhenguo Sun, Yi Diao, Cheng Zheng, Jianxin Sun, Yang Yang, Dehua Jiang

Open access · goldAbstract read
In one paragraph

Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 69 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. MiR-7 in Cancer Development.Biomedicines · 2021
    Review
  12. Review
  13. Role of microRNA-7 in liver diseases: a comprehensive review of the mechanisms and therapeutic applications.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Bo WangDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. wangboxuzhou@126.com.
Fei SunDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. sufei1981@126.com.
Nan DongDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. dongyutianqi@126.com.
Zhenguo SunDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. szgxuzhou@163.com.
Yi DiaoDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. hanyutianqi@163.com.
Cheng ZhengDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. zc2015@yeah.net.
Jianxin SunDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. sunjianxin2015@126.com.
Yang YangDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. yangyangxuzhou@yeah.net.
Dehua JiangDepartment of Neurosurgery, Xuzhou Central Hospital, Xuzhou, 221009, China. jingdehua1963@163.com.
Xuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies observed that altered energy metabolism has become widespread in cancer cells along with other cancer-associated traits that have been accepted as hallmarks of cancer. Akt signaling pathway is involved in the aerobic glycolysis program. However, mechanisms underlying the regulation of aerobic glycolysis and Akt activity in gliomas remain unclear. MicroRNAs are a group of small non-coding RNAs that can function as endogenous RNA interference to regulate expression of targeted genes. This study was conducted to detect the function of miR-7 targeting insulin-like growth factor 1 receptor (IGF-1R), which is an upstream regulator of Akt.

methodsMicroRNA expression data for gliomas and normal controls were downloaded from The Cancer Genome Atlas (TCGA) database. Quantitative real-time PCR was used to measure the microRNA-7 (miR-7) expression level, and Western blot was performed to detect protein expression in U87 and U251 cells. Colony formation assay and glycolysis stress test were also conducted. Luciferase reporter assay was used to identify the mechanism of IGF-1R and miR-7 regulation.

resultsmiR-7 was downregulated in human glioma tissues based on TCGA database. Forced expression of miR-7 or IGF-1R knockdown inhibited colony formation and glucose metabolic capabilities of glioma cells in vitro and decreased the p-Akt expression level. Bioinformatics analysis results indicated that IGF-1R could be a target of miR-7. Western blot and luciferase reporter assays showed that miR-7 modulated IGF-1R expression by directly targeting the binding site within the 3'-untranslated region.

conclusionsThis study provides the first evidence that miR-7 inhibits cellular growth and glucose metabolism in gliomas, at least partially, by regulating the IGF-1R/Akt signaling pathway. Therefore, miR-7 is a promising molecular drug for glioma treatment. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_211.

Indexed as

Cell ProliferationEnergy MetabolismBrain NeoplasmsCase-Control StudiesCell Line, TumorComputational BiologyDatabases, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticGliomaGlucoseHumansMicroRNAsOligonucleotide Array Sequence AnalysisProto-Oncogene Proteins c-aktReceptor, IGF Type 1GlucoseIGF1R protein, humanMicroRNAsMIRN7-1 microRNA, humanProto-Oncogene Proteins c-aktReceptor, IGF Type 1Receptors, Somatomedin

Identifiers

PMID25394492
PMCPMC4236426
OpenAlexW2161498998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.